Olema Pharmaceuticals (OLMA) Return on Capital Employed (2021 - 2026)
Olema Pharmaceuticals (OLMA) reported Return on Capital Employed of 41.62% for Q1 2026, down 630.0% year-over-year from 7.85% in Q1 2025, and up 8.9% quarter-over-quarter from 45.69% in Q4 2025.
Olema Pharmaceuticals (OLMA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 6 years of Return on Capital Employed data on file, last reported at 41.62% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 41.62%, down 630.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 41.62% (down 630.0% YoY), and the FY2025 annual result was 40.58%, up 358.0% from the prior year.
- Return on Capital Employed grew to 41.62% in Q1 2026 per OLMA's latest filing, from 45.69% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 28.68% in Q1 2022 and troughed at 64.21% in Q3 2024.
- A 5-year average of 46.76% and a median of 45.69% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed sank 3216 bps in 2023, then jumped 1590 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 51.62% in 2022, then increased by 23 bps to 39.87% in 2023, then slipped by 19 bps to 47.61% in 2024, then rose by 4 bps to 45.69% in 2025, then advanced by 9 bps to 41.62% in 2026.
- Business Quant data shows OLMA's Return on Capital Employed at 41.62% in Q1 2026, 45.69% in Q4 2025, and 50.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Olema Pharmaceuticals | 1.01 Bn | 1.01 Bn | - | -41.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.62% |
| Dec 31, 2025 | -45.69% |
| Sep 30, 2025 | -50.80% |
| Jun 30, 2025 | -43.33% |
| Mar 31, 2025 | -35.32% |
| Dec 31, 2024 | -47.61% |
| Sep 30, 2024 | -64.21% |
| Jun 30, 2024 | -52.29% |
| Mar 31, 2024 | -44.94% |
| Dec 31, 2023 | -39.87% |
| Sep 30, 2023 | -46.42% |
| Jun 30, 2023 | -59.14% |
| Mar 31, 2023 | -60.84% |
| Dec 31, 2022 | -51.62% |
| Sep 30, 2022 | -44.38% |
| Jun 30, 2022 | -38.17% |
| Mar 31, 2022 | -28.68% |
| Dec 31, 2021 | -24.33% |
| Sep 30, 2021 | -19.49% |
| Jun 30, 2021 | -15.68% |